Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?

NCT ID NCT03034356

Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether levetiracetam, a drug used for seizures, can reduce overactivity in the hippocampus—a brain area linked to memory—and improve cognitive function in people with schizophrenia or schizoaffective disorder. Participants receive either levetiracetam or a placebo, and researchers measure changes in brain activity using fMRI and assess thinking skills with a standard test. The goal is to see if calming this brain region can help with the memory and thinking problems that often accompany schizophrenia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
levetiracetam (an anti-seizure drug)
What this could lead to
If it works, levetiracetam could offer a new way to improve memory and thinking in people with schizophrenia.
What could go wrong
This is an early-stage trial with a small number of participants, so results may not hold up in larger studies. The drug may also cause side effects like dizziness or sleepiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

67 people

The number who actually took part.

Started

Aug 2018

Finished

Jun 2024

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of schizophrenia or schizoaffective disorder * Good general health * Normal vital signs (blood pressure, pulse, respiration) Exclusion Criteria: * Substance abuse * Significant neurological disorders * Significant head trauma/injury * Pregnancy * MRI-specific exclusion criteria, e.g.,: * claustrophobia * weight\>400 lbs * metal in the body

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

Contacts and locations

Locations

  • Rocky Mountain Regional VA Medical Center, Aurora, CO

    Aurora, Colorado, 80045-7211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.